Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-1188 in Advanced Malignancies
NCT05144334Phase 1Terminated
- Sponsor
- Biotheryx
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of sontigidomide in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and solid tumor (7 cohorts), sponsored by Biotheryx. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Recommended Phase 2 Dose at 28 days. Started Jan 2022; status: terminated.
02
Drugs
sontigidomide
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)solid tumor
Beyond the preview
Go deeper on NCT05144334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144334.